The effect of prednisolone and/or acyclovir in relation to severity of Bell’s palsy at presentation  by Abdelghany, Ahmed Mohammed & Kamel, Samer Badee
Egyptian Journal of Ear, Nose, Throat and Allied Sciences (2013) 14, 155–159Egyptian Society of Ear, Nose, Throat and Allied Sciences
Egyptian Journal of Ear, Nose, Throat and Allied
Sciences
www.ejentas.comORIGINAL ARTICLEThe eﬀect of prednisolone and/or acyclovir in relation
to severity of Bell’s palsy at presentationAhmed Mohammed Abdelghany *, Samer Badee KamelDepartment of Otorhinolaryngolgy, Benha University, EgyptReceived 11 December 2012; accepted 9 April 2013
Available online 9 May 2013*
E
ho
Pe
Th
20
htKEYWORDS
Bell’s;
Prednisolone;
Acyclovir;
SeverityCorresponding author.
-mail addresses: ahmedent
tmail.com (A.M. Abdelghan
er review under responsibili
roat and Allied Sciences.
Production an
90-0740 ª 2013 Production
tp://dx.doi.org/10.1016/j.ejen@gmail.c
y).
ty of Eg
d hostin
and hosti
ta.2013.0Abstract Objectives: To evaluate the efﬁcacy of prednisolone and/or acyclovir in the treatment of
Bell’s palsy in relation to severity at the ﬁrst visit.
Design: A prospective, randomised, placebo-controlled study.
Setting: Four public outpatient ENT clinics.
Patients: 603 patients aged 18–70 years were treated within 72 h of palsy onset. Patients were
assigned to three groups; group 1 treatedwithprednisoloneplus placebo (n= 198), group 2 treatedwith
acyclovir plus placebo (n= 203), and group 3 treated with prednisolone plus acyclovir (n= 202). Each
group was divided into three subgroups according to severity of palsy at presentation using the Sunny-
brook score; severe; moderate and mild. Point of assessment was at the end of the 12th month.
Main outcomemeasures: Facial function and synkinesis were evaluated for correlation to severity of
palsy at baseline.
Results: In patients with severe palsy, complete recovery at 12 months was 56% with prednisolone,
41.6%with acyclovir and 55.5% in prednisolone plus acyclovir group. In patients withmoderate palsy,
recovery was 64.5%, 56.6% and 70.2% in groups 1, 2 and 3 respectively. In patients with mild palsy,
recovery was 92%, 62.6% and 91.5% in groups 1, 2 and 3, respectively. Complete recovery and absence
of slinkiness results were correlated to the baseline severity. Group 3 had signiﬁcant higher results in
moderate palsy cases.
Conclusion: Prednisolone treatment resulted in higher complete recovery rates, regardless of severity
at presentation. Prednisolone treatment should be considered in all patients irrespective of degree of
palsy.
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4.0031. Introduction
Bell’s palsy is an abrupt onset of unilateral weakness or paral-
ysis of the face with no obvious cause.1 The annual incidence is
about 30 per 100,000 population, with no seasonal or geo-
graphical clustering and with a peak incidence between the sec-
ond and fourth decades of life.2,3gyptian Society of Ear, Nose, Throat and Allied Sciences.
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herpes virus, with subsequent inﬂammation and entrapment
of the facial nerve in the narrow labyrinthine segment, is one
proposed mechanism for the nerve injury.4,5
In most cases, the natural course of Bell’s palsy is favour-
able; however, approximately 30% of patients will suffer some
sequelae, and 4% will have severe sequelae with contracture
and/or synkinesis.2
Treatment for Bell’s palsy is aimed to prevent sequelae and
is based on the presumed pathophysiology of herpes virus
infection and inﬂammation of the facial nerve.6,7 In a recent
study, it was stated that corticosteroids signiﬁcantly increased
the frequency of complete recovery from Bell’s palsy.8 In a
study done by Lockhart et al.6 with 1987 patients in seven tri-
als, however, a signiﬁcant beneﬁt from antivirals compared
with placebo was not shown.
Previous studies have reported that severe palsy is a nega-
tive prognostic factor for recovery from Bell’s palsy.9–12 De-
spite the ﬁnding that corticosteroids improve the recovery
rates in Bell’s palsy, the treatment effect in relation to severity
of palsy at presentation is largely unknown. In the study done
by Lockhart et al.6 it was concluded that subgroup analysis of
existing data and further studies should be performed to assess
the impact of baseline severity of palsy on the outcome of
treatment. According to Linder et al.,13 studies are needed to
verify any beneﬁt of medical treatment in Bell’s palsy and her-
pes zoster oticus paralysis; such studies would have to include
analysis of the severity of palsy at baseline.
The aim of the present study is to study the treatment effect
of prednisolone and/or acyclovir on outcome of Bell’s palsy in
relation to severity of palsy at presentation.2. Patients and methods
2.1. Patients
Patients with acute unilateral peripheral facial palsy were
screened by the ear, nose and throat physicians at four public
Otorhinolaryngology clinics in Kalubia-Egypt (Benha Univer-
sity Hospital, Benha Insurance Hospital, Benha Educational
Hospital and Toukh Insurance Clinic) between January 2010
and May 2012. 625 patients aged 18–70 years with palsy onset
within 72 h were considered for inclusion.
Cases presenting after more than 72 h since onset of palsy
or patients younger than 18 years or older than 70 years, as
well as unwillingness to participate, diabetes mellitus, previous
facial palsy, pregnancy or breastfeeding, other neurological
diseases, uncontrolled hypertension and psychiatric diseases
were excluded from the study.14
All patients and parents of patients under 21 years old were
informed about the study trial and written consents were
signed.
Using sealed envelops, patients were randomly allocated in
three groups, group 1 included 208 patients and received pred-
nisolone plus placebo, group 2 included 208 patients and re-
ceived acyclovir plus placebo and group 3 included 209
patients and received prednisolone plus acyclovir.
Grading of facial function was performed by senior ENT
specialists using the Sunnybrook facial grading system at start
of treatment/baseline at the ﬁrst visit, and at every follow-up
visit. The Sunnybrook grading system is a regionally weightedsystem that evaluates resting symmetry, degree of voluntary
movements and synkinesis. Scores are summed to form a score
of 0–100, where 0 is complete paralysis and 100 represents nor-
mal functions.15,16
Patients in each group were divided into three groups
according to severity of palsy at presentation using the
Sunnybrook score: severe (Sunnybrook score 0–20); moderate
(Sunnybrook score 21–40) and mild (Sunnybrook score
>40)16.
2.2. Procedures
Prednisolone 5 mg (or placebo matched for smell, colour and
size) was given as 60 mg daily for 5 days, then tapering by
10 mg per day for 5 days, to give a total treatment time of
10 days. Acyclovir (or placebo matched for smell, colour and
size) was given as two 200-mg tablets three times daily for
7 days. Follow-up visits were scheduled at day 14 and at 1,
2, 3, 6 and 12 months. If recovery was complete (Sunnybrook
score of 100) in the ﬁrst months, the next follow-up was at
12 months. Team physicians and patients were blinded for
the treatment drugs.
Synkinesis at 12 months was assessed with the Sunnybrook
system and classiﬁed as present or not present.
The results in this study were presented using Sunnybrook
scores because the Sunnybrook facial grading system is more
sensitive to sequelae and it is also more reliable.17–19
Total recovery at 12 months (Sunnybrook score = 100)
and the presence of synkinesis at 12 months were evaluated
for correlation to severity of palsy at baseline.
2.3. Statistical analysis
The differences in Sunnybrook scores at 12 months between
treatment groups were compared by calculating two-sided p-
values based on Wilcoxon’s rank sum test. Categorical vari-
ables were compared using Fisher’s exact test. Univariate
Cox proportional hazards models were used to estimate the
hazard ratio of recovery. The log rank test was used to test
the null hypothesis that there is no difference between treat-
ment groups at any timepoint, taking whole follow-up period
into account. All computations were carried out using SPSS
software, version 16.
3. Results
In total, 625 patients (331 men, 294 women) were included in
the study. Of these, 208 received prednisolone plus placebo,
208 acyclovir plus placebo and 209 prednisolone plus acyclo-
vir. Of the 625 patients, 603 (315 men, 288 women) attended
the 12-month follow-up visit. Age and treatment start were
similar in the three groups.
Mean age was 45.82 years (± 14.95) in the patients with se-
vere palsy, 43.87 years (± 14.96) in the moderate and
39.80 years (± 13.51) in the mild palsy group.
Patients with severe palsy at baseline had a mean time to
treatment start of 48.42 h (sd ± 18.7), while the time to treat-
ment start for moderate palsy was 38.76 h (sd ± 14.72) and for
mild palsy, 41.47 h (sd ± 17.5).
In group 1, prednisolone showed signiﬁcant success regard-
ing complete recovery and absence of slinkiness in all cases,
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were obtained in mild cases and lower results with severe cases
(Table 1).
In group 2, acyclovir showed signiﬁcant success regarding
complete recovery and absence of slinkiness in all cases, this
was also correlated to the baseline severity where higher results
were obtained in mild cases and lower results with severe cases
(Table 2).
In group 3, prednisolone and acyclovir showed signiﬁcant
success regarding complete recovery and absence of slinkiness
in all cases, this was also correlated to the baseline severity
where higher results were obtained in mild cases and lower re-
sults with severe cases (Table 3).
Comparing the results of the three groups, there was a sig-
niﬁcant difference between group 1 and 2 results (p< .05)
reﬂecting higher results of prednisolone above acyclovir alone
regardless of the severity of cases. There was no signiﬁcant dif-
ference between group 1 and 3 results in severe and mild cases
while group 3 showed higher results in the moderate group
cases (p< .05) as shown in Table 4.
Time to complete recovery was signiﬁcantly shorter for
groups 1 and 3 for the three severity groups. As expected, mild
cases showed signiﬁcant shorter time for complete recovery
than moderate and severe cases. Acyclovir did not add a signif-
icant difference to prednisolone regarding this time.
The mean Sunnybrook scores at 12 months were correlated
to the severity in all groups where mild cases showed higher
scores and severe cases showed lower scores as shown in Ta-
ble 5 and Fig. 1.Table 1 The effect of prednisolone (plus placebo) on recovery and
Degree of palsy No. of patients at presentation Recovered patients a
No. %
Severe 32 18 56
Moderate 79 51 64
Mild 87 80 92
Total 198 148 74
Table 2 The effect of acyclovir (plus placebo) on recovery and syn
Degree of palsy No. of patients at presentation Recovered patients a
No. %
Severe 29 10 41
Moderate 75 42 56
Mild 99 62 62
Total 203 114 56
Table 3 The effect of prednisolone plus acyclovir on recovery and
Degree of palsy No. of patients at presentation Recovered patients a
No %
Severe 36 20 55
Moderate 84 59 70
Mild 82 75 91
Total 202 148 73Synkinesis was present in higher percentage in group 2 (acy-
clovir group) with no signiﬁcant difference between groups 1
and 3, as shown in Table 6.
4. Discussion
Patients with severe, moderate and mild palsy at presentation,
all had signiﬁcantly higher complete recovery rates if treated
with prednisolone compared with acyclovir. Synkinesis at
12 months was also signiﬁcantly less common in patients when
treated with prednisolone as compared with acyclovir in the
three severity categories.
In our study, patients with moderate palsy at baseline who
were treated with prednisolone plus acyclovir had signiﬁcantly
higher complete recovery rates compared with those treated
with prednisolone plus placebo and with acyclovir plus pla-
cebo groups.
At the initial visit, the physician cannot predict if the palsy
will deteriorate or not. In a study by Linder et al.13 36% of pa-
tients, almost all treated with steroids, deteriorated to total
paralysis within 2 weeks. Marsk et al.20 found that 236/829
(28%) patients with Bell’s palsy deteriorated within the ﬁrst
11-17 days after onset of palsy and that early treatment with
prednisolone reduced the number of patients who deteriorated.
Steroid treatment may reduce inﬂammation and thus pre-
vents further nerve damage. As at present we do not have
any diagnostic tool that can, at the initial visit, predict the
course and outcome for the individual patient, it seems ade-
quate to treat the patient regardless of severity of palsy. Evensynkinesis.
t 12 months Mean Sunnybrook score 12 months Synkinesis
No. %
87 11 34.4
.5 91 18 22.8
96 6 6.9
.7 35 17.7
kinesis.
t 12 months Mean Sunnybrook score 12 months Synkinesis
No. %
.6 72 14 48.3
87 21 28
.6 85 13 13
.2 48 23.6
synkinesis.
t 12 months Mean Sunnybrook score 12 months Synkinesis
No %
.5 89 12 33.3
.2 93 17 20.2
.5 95 5 6
.3 34 16.8
Table 4 Comparison between the three groups regarding recovery rates.
Sunnybrook score Group1 (Prednisolone + placebo) Group 2 (Acyclovir + placebo) Group 3 (Prednisolone + Acyclovir)
No. % No. % No. %
Severe 18 56 10 41.6 20 55.5
Moderate 51 64.5 42 56.6 59 70.2
Mild 80 92 62 62.6 75 91.5
Table 5 Comparison between the three groups regarding
Sunnybrook score at 12 months.
Group 1 Group 2 Group 3
Severe (<20) 87 72 89
Moderate (21–40) 91 87 93
Mild (>40) 96 85 95
Table 6 Comparison between the three groups regarding
synkinesis.
Group 1 Group 2 Group 3
No. % No. % No %
Severe 11 34.4 14 48.3 12 33.3
Moderate 18 22.8 21 28 17 20.2
Mild 6 6.9 13 13 5 6
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roids, which is in accordance with other results that treatment
with prednisolone within 48 h of onset of palsy gave signiﬁ-
cantly higher recovery rates and less synkinesis compared with
no prednisolone.21
The addition of acyclovir to prednisolone did not have any
signiﬁcant additional effect regarding complete recovery or
presence of synkinesis in the severe and mild groups. This is
not in accordance with the ﬁndings of Hato et al.22 Patients
in that study were treated with valaciclovir, 1000 mg/day com-
pared with 1200 mg/ day acyclovir in our study, they reported
a better outcome with the combination therapy of predniso-
lone and valaciclovir in cases of complete or severe palsy. In
a study by Minnerop et al.23 the combination of prednisolone
with famciclovir was reported to be more effective in cases with
severe palsy.
Our ﬁndings concerning acyclovir plus placebo are in accor-
dance with those of the Cochrane review ‘Antiviral treatment
for Bell’s palsy’ including seven trials with altogether 1987 pa-
tients.6 It was concluded that moderate quality evidence shows
that antivirals are signiﬁcantly less likely to produce complete
recovery compared with corticosteroids.Fig. 1 Comparison between the three groupsAcyclovir group results were not signiﬁcantly different from
other studies that were performed using placebo alone in the
treatment of Bell’s palsy. In a study done by Axelsson
et al.24 in patients with severe to mild palsy at baseline, valac-
iclovir had no effect on complete recovery rates compared with
placebo. There was no signiﬁcant effect of valaciclovir alone
on the presence of synkinesis at 12 months in any of the three
different severity groups at baseline.24
In accordance with previous studies,10–12,22 severity at base-
line in the present study was correlated to outcome. Conse-
quently, a low Sunnybrook value at baseline was correlated
to a less favourable outcome.
5. Conclusion
Bell’s palsy patients given prednisolone had signiﬁcantly better
outcome, regardless of severity of palsy at presentation, com-
pared with patients not treated with prednisolone. Acyclovir
had an additional effect to prednisolone in moderate cases ofregarding Sunnybrook score at 12 months.
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study was correlated to outcome.
We therefore recommend treatment with prednisolone
regardless of severity at initial visit in adult patients with Bell’s
palsy as long as no contraindications for steroid treatment are
present. We also recommend the addition of acyclovir to pred-
nisolone in cases categorised as moderate palsy at
presentation.
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